These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

850 related items for PubMed ID: 27775825

  • 1. Impact of type of calcineurin inhibitor on post-transplant tuberculosis: Single-center study from India.
    Agarwal SK, Bhowmik D, Mahajan S, Bagchi S.
    Transpl Infect Dis; 2017 Feb; 19(1):. PubMed ID: 27775825
    [Abstract] [Full Text] [Related]

  • 2. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
    Anil Kumar MS, Irfan Saeed M, Ranganna K, Malat G, Sustento-Reodica N, Kumar AM, Meyers WC.
    Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
    [Abstract] [Full Text] [Related]

  • 3. An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients.
    Sommerer C, Suwelack B, Dragun D, Schenker P, Hauser IA, Witzke O, Hugo C, Kamar N, Merville P, Junge M, Thaiss F, Nashan B, Athena Study Group.
    Kidney Int; 2019 Jul; 96(1):231-244. PubMed ID: 31027892
    [Abstract] [Full Text] [Related]

  • 4. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
    Gruessner RW.
    Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719
    [Abstract] [Full Text] [Related]

  • 5. Mycophenolate mofetil decreases rejection in simultaneous pancreas-kidney transplantation when combined with tacrolimus or cyclosporine.
    Stegall MD, Simon M, Wachs ME, Chan L, Nolan C, Kam I.
    Transplantation; 1997 Dec 27; 64(12):1695-700. PubMed ID: 9422404
    [Abstract] [Full Text] [Related]

  • 6. Conversion from tacrolimus to cyclosporine in patients with new-onset diabetes after renal transplant: an open-label randomized prospective pilot study.
    Rathi M, Rajkumar V, Rao N, Sharma A, Kumar S, Ramachandran R, Kumar V, Kohli HS, Gupta KL, Sakhuja V.
    Transplant Proc; 2015 May 27; 47(4):1158-61. PubMed ID: 26036543
    [Abstract] [Full Text] [Related]

  • 7. Impact of Tacrolimus Compared With Cyclosporin on the Incidence of Acute Allograft Rejection in Human Immunodeficiency Virus-Positive Kidney Transplant Recipients.
    Gathogo E, Harber M, Bhagani S, Levy J, Jones R, Hilton R, Davies G, Post FA, UK HIV Kidney Transplantation Study Group.
    Transplantation; 2016 Apr 27; 100(4):871-8. PubMed ID: 26413990
    [Abstract] [Full Text] [Related]

  • 8. Immune monitoring with a lymphocyte adenosine triphosphate assay in kidney transplant recipients treated with a calcineurin inhibitor.
    Sugiyama K, Tsukaguchi M, Toyama A, Satoh H, Saito K, Nakagawa Y, Takahashi K, Tanaka S, Onda K, Hirano T.
    Exp Clin Transplant; 2014 Jun 27; 12(3):195-9. PubMed ID: 24907718
    [Abstract] [Full Text] [Related]

  • 9. Randomized controlled study comparing reduced calcineurin inhibitors exposure versus standard cyclosporine-based immunosuppression.
    Hernández D, Miquel R, Porrini E, Fernández A, González-Posada JM, Hortal L, Checa MD, Rodríguez A, García JJ, Rufino M, Torres A.
    Transplantation; 2007 Sep 27; 84(6):706-14. PubMed ID: 17893603
    [Abstract] [Full Text] [Related]

  • 10. Side effects and efficacy of renal sparing immunosuppression in pediatric liver transplantation-A single center matched cohort study.
    Leiskau C, Rajanayagam J, Pfister ED, Goldschmidt I, Junge N, Karch A, Lerch C, Richter N, Lehner F, Schrem H, Baumann U.
    Pediatr Transplant; 2018 Aug 27; 22(5):e13207. PubMed ID: 29729061
    [Abstract] [Full Text] [Related]

  • 11. Calcineurin Inhibitor Nephrotoxicity Through the Lens of Longitudinal Histology: Comparison of Cyclosporine and Tacrolimus Eras.
    Nankivell BJ, PʼNg CH, OʼConnell PJ, Chapman JR.
    Transplantation; 2016 Aug 27; 100(8):1723-31. PubMed ID: 27306529
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results.
    Krämer BK, Montagnino G, Del Castillo D, Margreiter R, Sperschneider H, Olbricht CJ, Krüger B, Ortuño J, Köhler H, Kunzendorf U, Stummvoll HK, Tabernero JM, Mühlbacher F, Rivero M, Arias M, European Tacrolimus vs Cyclosporin Microemulsion Renal Transplantation Study Group.
    Nephrol Dial Transplant; 2005 May 27; 20(5):968-73. PubMed ID: 15741208
    [Abstract] [Full Text] [Related]

  • 13. Prednisone withdrawal 14 days after liver transplantation with mycophenolate: a prospective trial of cyclosporine and tacrolimus.
    Stegall MD, Wachs ME, Everson G, Steinberg T, Bilir B, Shrestha R, Karrer F, Kam I.
    Transplantation; 1997 Dec 27; 64(12):1755-60. PubMed ID: 9422416
    [Abstract] [Full Text] [Related]

  • 14. Clinical outcome in heart transplant recipients receiving everolimus in combination with dosage reduction of the calcineurin inhibitor cyclosporine A or tacrolimus.
    Fuchs U, Zittermann A, Ensminger SM, Schulz U, Gummert JF.
    Transpl Immunol; 2014 Aug 27; 31(2):87-91. PubMed ID: 24932812
    [Abstract] [Full Text] [Related]

  • 15. Conversion from tacrolimus-mycophenolate mofetil to tacrolimus-mTOR immunosuppression after kidney-pancreas transplantation reduces the incidence of both BK and CMV viremia.
    Knight RJ, Graviss EA, Nguyen DT, Kuten SA, Patel SJ, Gaber L, Gaber AO.
    Clin Transplant; 2018 Jun 27; 32(6):e13265. PubMed ID: 29676018
    [Abstract] [Full Text] [Related]

  • 16. Cyclosporine A versus tacrolimus in combination with mycophenolate mofetil and steroids as primary immunosuppression after lung transplantation: one-year results of a 2-center prospective randomized trial.
    Zuckermann A, Reichenspurner H, Birsan T, Treede H, Deviatko E, Reichart B, Klepetko W.
    J Thorac Cardiovasc Surg; 2003 Apr 27; 125(4):891-900. PubMed ID: 12698153
    [Abstract] [Full Text] [Related]

  • 17. Time-Dependent and Immunosuppressive Drug-Associated Adverse Event Profiles in De Novo Kidney Transplant Recipients Converted from Tacrolimus to Sirolimus Regimens.
    Felix MJ, Felipe CR, Tedesco-Silva H, Osmar Medina-Pestana J.
    Pharmacotherapy; 2016 Feb 27; 36(2):152-65. PubMed ID: 26799522
    [Abstract] [Full Text] [Related]

  • 18. Cryptosporidium infection after renal transplantation in an endemic area.
    Bhadauria D, Goel A, Kaul A, Sharma RK, Gupta A, Ruhela V, Gupta A, Vardhan H, Prasad N.
    Transpl Infect Dis; 2015 Feb 27; 17(1):48-55. PubMed ID: 25620388
    [Abstract] [Full Text] [Related]

  • 19. Association of immunosuppressive maintenance regimens with posttransplant lymphoproliferative disorder in kidney transplant recipients.
    Sampaio MS, Cho YW, Shah T, Bunnapradist S, Hutchinson IV.
    Transplantation; 2012 Jan 15; 93(1):73-81. PubMed ID: 22129761
    [Abstract] [Full Text] [Related]

  • 20. Randomized trial of cyclosporine and tacrolimus therapy with steroid withdrawal in living-donor renal transplantation: 5-year follow-up.
    Lee YJ, Kim B, Lee JE, Kim YG, Kim DJ, Kim SJ, Joh JW, Oh HY, Huh W.
    Transpl Int; 2010 Feb 15; 23(2):147-54. PubMed ID: 19744223
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 43.